Sanofi, Regeneron's IL-33 drug fails one of 2 COPD studies as FDA timeline thrown in doubt
Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the Regeneron-partnered drug failed one of a pair of phase 3 COPD trials.
Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the Regeneron-partnered drug failed one of a pair of phase 3 COPD trials.
